Clearside Biomedical, a startup focused on eye health, is off to a fast start.
The company, which is based in Atlanta with research and development taking place in the Triangle, has landed $4 million in venture funding from Triangle-based Hatteras Venture Partners.
Christy Shaffer, the long-time head of Inspire Pharmaceuticals who is a partner at Hatteras, will serve as chair of the Clearside board.
The company is already testing an ocular microinjection platform and also has a product under development to treat macular edema and retina vein occlusion.
Ben Yerza, a former Inspire executive, is head of research and development.
Daniel While, the chief executive officer, formerly worked with an Atlanta eye-care technology firm backed by Intersouth Partners in Durham.
“Clearside Biomedical represents an ideal fit for Hatteras Discovery as the platform technology is highly innovative, based on elegant science and the lead product is expected to be in clinical trials in the US in less than 18 months,” Shaffer said in a statement.
Clearside’s technology was developed by researchers at Georgia Tech and Emory University through work done by Mark Prausnitz at Tech and Henry Edelhauser at Emory. Both own equity in Clearside.
Some individuals also invested in the company.
Emory University and Georgia Tech also have a financial interest in the firm
“Clearside Biomedical is delighted to have a partnership with the seasoned Hatteras investment team and their extensive experience in building healthcare companies,” White said.
“Together, we plan to continue the development of Clearside Biomedical’s ocular microinjection platform into important ophthalmic therapeutics by providing retinal surgeons the ability to have an in-office injection procedure for the suprachoroidal space, a tissue space where we have demonstrated improved drug characteristics in vivo when compared to traditional intravitreal injection.”
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.